Gross hematuria after SARS-CoV-2 vaccination: questionnaire survey in Japan.
Coronavirus 2019
Gross hematuria
IgA nephropathy
SARS-CoV-2 vaccination
mRNA vaccination
Journal
Clinical and experimental nephrology
ISSN: 1437-7799
Titre abrégé: Clin Exp Nephrol
Pays: Japan
ID NLM: 9709923
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
29
09
2021
accepted:
04
11
2021
pubmed:
14
11
2021
medline:
25
3
2022
entrez:
13
11
2021
Statut:
ppublish
Résumé
Recent clinical reports indicate a correlation between gross hematuria after the coronavirus 2019 (COVID-19) vaccination in patients with glomerulonephritis, especially immunoglobulin A nephropathy (IgAN). Furthermore, healthcare workers in Japan were initially vaccinated with an mRNA vaccine from February 17, 2021, and some of them experienced gross hematuria after receiving the vaccination. We conducted a web-based survey of the councilor members of the Japanese Society of Nephrology (581 members, 382 facilities) to elucidate the relationship between gross hematuria and COVID-19 vaccination. In the first survey, 27 cases (female: 22, 81.5%) of gross hematuria were reported after receiving a COVID-19 vaccination. Of them, 19 (70.4%) patients were already diagnosed with IgAN at the occurrence of gross hematuria. Proteinuria appeared in eight of the 14 (57.1%) cases with no proteinuria before vaccination and hematuria in five of the seven (71.4%) cases with no hematuria before vaccination. The second survey revealed that a renal biopsy was performed after vaccination in four cases, all of whom were diagnosed with IgAN. Only one case showed a slightly increased serum creatinine level, and no patients progressed to severe renal dysfunction. This study clarified the clinical features of gross hematuria after a COVID-19 vaccination. Because there was no obvious progression to severe renal dysfunction, safety of the COVID-19 vaccination is warranted at least in the protocol of inoculation twice.
Sections du résumé
BACKGROUND
BACKGROUND
Recent clinical reports indicate a correlation between gross hematuria after the coronavirus 2019 (COVID-19) vaccination in patients with glomerulonephritis, especially immunoglobulin A nephropathy (IgAN). Furthermore, healthcare workers in Japan were initially vaccinated with an mRNA vaccine from February 17, 2021, and some of them experienced gross hematuria after receiving the vaccination.
METHODS
METHODS
We conducted a web-based survey of the councilor members of the Japanese Society of Nephrology (581 members, 382 facilities) to elucidate the relationship between gross hematuria and COVID-19 vaccination.
RESULTS
RESULTS
In the first survey, 27 cases (female: 22, 81.5%) of gross hematuria were reported after receiving a COVID-19 vaccination. Of them, 19 (70.4%) patients were already diagnosed with IgAN at the occurrence of gross hematuria. Proteinuria appeared in eight of the 14 (57.1%) cases with no proteinuria before vaccination and hematuria in five of the seven (71.4%) cases with no hematuria before vaccination. The second survey revealed that a renal biopsy was performed after vaccination in four cases, all of whom were diagnosed with IgAN. Only one case showed a slightly increased serum creatinine level, and no patients progressed to severe renal dysfunction.
CONCLUSION
CONCLUSIONS
This study clarified the clinical features of gross hematuria after a COVID-19 vaccination. Because there was no obvious progression to severe renal dysfunction, safety of the COVID-19 vaccination is warranted at least in the protocol of inoculation twice.
Identifiants
pubmed: 34773533
doi: 10.1007/s10157-021-02157-x
pii: 10.1007/s10157-021-02157-x
pmc: PMC8590432
doi:
Substances chimiques
COVID-19 Vaccines
0
Creatinine
AYI8EX34EU
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
316-322Subventions
Organisme : Arthritis Research UK
ID : FC001045
Pays : United Kingdom
Organisme : Ministry of Health, Labour and Welfare
ID : 20FC1045
Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2021. The Author(s).
Références
Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med. 2020;383:2427–38.
doi: 10.1056/NEJMoa2028436
Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603–15.
doi: 10.1056/NEJMoa2034577
Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99–111.
doi: 10.1016/S0140-6736(20)32661-1
Sadoff J, Gray G, Vandebosch A, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med. 2021;384:2187–201.
doi: 10.1056/NEJMoa2101544
Al Kaabi N, Zhang Y, Xia S, et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA. 2021;326:35–45.
doi: 10.1001/jama.2021.8565
Zhu FC, Guan XH, Li YH, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020;396:479–88.
doi: 10.1016/S0140-6736(20)31605-6
Official Website of the Prime Minister of Japan and His cabinet, “Vaccinating order”. 2021. https://japan.kantei.go.jp/ongoingtopics/pdf/202105_vaccinating_order.pdf . Accessed 30 September 2021.
Official Website of the Prime Minister of Japan and His cabinet, “Total number of vaccine doses administered to date”. 2021. https://japan.kantei.go.jp/ongoingtopics/vaccine.html . Accessed 30 Sep 2021.
Negrea L, Rovin BH. Gross hematuria following vaccination for severe acute respiratory syndrome coronavirus 2 in 2 patients with IgA nephropathy. Kidney Int. 2021;99:1487.
doi: 10.1016/j.kint.2021.03.002
Rahim SEG, Lin JT, Wang JC. A case of gross hematuria and IgA nephropathy flare-up following SARS-CoV-2 vaccination. Kidney Int. 2021;100:238.
doi: 10.1016/j.kint.2021.04.024
Tan HZ, Tan RY, Choo JCJ, et al. Is COVID-19 vaccination unmasking glomerulonephritis? Kidney Int. 2021;100:469–71.
doi: 10.1016/j.kint.2021.05.009
Perrin P, Bassand X, Benotmane I, et al. Gross hematuria following SARS-CoV-2 vaccination in patients with IgA nephropathy. Kidney Int. 2021;100:466–8.
doi: 10.1016/j.kint.2021.05.022
Hanna C, Herrera Hernandez LP, Bu L, et al. IgA nephropathy presenting as macroscopic hematuria in 2 pediatric patients after receiving the Pfizer COVID-19 vaccine. Kidney Int. 2021;100:705–6.
doi: 10.1016/j.kint.2021.06.032
Schena FP, Nistor I. Epidemiology of IgA nephropathy: a global perspective. Semin Nephrol. 2018;38:435–42.
doi: 10.1016/j.semnephrol.2018.05.013
Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16:626–38.
doi: 10.1038/nri.2016.90
Klein SL, Marriott I, Fish EN. Sex-based differences in immune function and responses to vaccination. Trans R Soc Trop Med Hyg. 2015;109:9–15.
doi: 10.1093/trstmh/tru167
Pardi N, Hogan MJ, Naradikian MS, et al. Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. J Exp Med. 2018;215:1571–88.
doi: 10.1084/jem.20171450
Lind NA, Rael VE, Pestal K, et al. Regulation of the nucleic acid-sensing Toll-like receptors. Nat Rev Immunol. 2021. https://doi.org/10.1038/s41577-021-00577-0 .
doi: 10.1038/s41577-021-00577-0
pubmed: 34272507
pmcid: 8283745
Suzuki H, Kiryluk K, Novak J, et al. The pathophysiology of IgA nephropathy. J Am Soc Nephrol. 2011;22:1795–803.
doi: 10.1681/ASN.2011050464
Suzuki H, Suzuki Y, Narita I, et al. Toll-like receptor 9 affects severity of IgA nephropathy. J Am Soc Nephrol. 2008;19:2384–95.
doi: 10.1681/ASN.2007121311
Makita Y, Suzuki H, Kano T, et al. TLR9 activation induces aberrant IgA glycosylation via APRIL- and IL-6-mediated pathways in IgA nephropathy. Kidney Int. 2020;97:340–9.
doi: 10.1016/j.kint.2019.08.022
Zheng N, Xie K, Ye H, et al. TLR7 in B cells promotes renal inflammation and Gd-IgA1 synthesis in IgA nephropathy. JCI Insight. 2020;5: e136965.
doi: 10.1172/jci.insight.136965